These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23999217)

  • 41. The chemoprevention of prostate cancer and the Prostate Cancer Prevention Trial.
    Brawley OW; Thompson IM
    Cancer Treat Res; 1996; 88():189-200. PubMed ID: 9239480
    [No Abstract]   [Full Text] [Related]  

  • 42. Circadian genes and risk of prostate cancer in the prostate cancer prevention trial.
    Chu LW; Till C; Yang B; Tangen CM; Goodman PJ; Yu K; Zhu Y; Han S; Hoque AM; Ambrosone C; Thompson I; Leach R; Hsing AW
    Mol Carcinog; 2018 Mar; 57(3):462-466. PubMed ID: 29318656
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer.
    Ankerst DP; Thompson IM
    Arch Ital Urol Androl; 2006 Dec; 78(4):154-6. PubMed ID: 17269622
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemoprevention of prostate cancer with finasteride.
    Thompson I; Feigl P; Coltman C
    Important Adv Oncol; 1995; ():57-76. PubMed ID: 7672814
    [No Abstract]   [Full Text] [Related]  

  • 45. Finasteride, a selective 5-alpha-reductase inhibitor, in the prevention and treatment of human prostate cancer.
    Reddy GK
    Clin Prostate Cancer; 2004 Mar; 2(4):206-8. PubMed ID: 15072601
    [No Abstract]   [Full Text] [Related]  

  • 46. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.
    Redman MW; Tangen CM; Goodman PJ; Lucia MS; Coltman CA; Thompson IM
    Cancer Prev Res (Phila); 2008 Aug; 1(3):174-81. PubMed ID: 19138953
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The PCPT study: the viewpoint of an urologist involved].
    Fourcade RO
    Ann Urol (Paris); 2004 Dec; 38 Suppl 2():S29-34. PubMed ID: 15651488
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
    Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
    J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The influence of finasteride on the development of prostate cancer.
    Thompson IM; Goodman PJ; Tangen CM; Lucia MS; Miller GJ; Ford LG; Lieber MM; Cespedes RD; Atkins JN; Lippman SM; Carlin SM; Ryan A; Szczepanek CM; Crowley JJ; Coltman CA
    N Engl J Med; 2003 Jul; 349(3):215-24. PubMed ID: 12824459
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does Proscar prevent prostate cancer?
    Johns Hopkins Med Lett Health After 50; 2008 Oct; 20(8):3. PubMed ID: 18958922
    [No Abstract]   [Full Text] [Related]  

  • 51. Impact of metabolic syndrome on response to medical treatment of benign prostatic hyperplasia.
    Cyrus A; Kabir A; Goodarzi D; Talaei A; Moradi A; Rafiee M; Moghimi M; Shahbazi E; Farmani E
    Korean J Urol; 2014 Dec; 55(12):814-20. PubMed ID: 25512816
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Can chemoprevention reduce the risk of prostate cancer?
    Diamandis EP
    Clin Chem; 2010 Aug; 56(8):1214-5. PubMed ID: 20567025
    [No Abstract]   [Full Text] [Related]  

  • 53. Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease.
    Hoque A; Yao S; Till C; Kristal AR; Goodman PJ; Hsing AW; Tangen CM; Platz EA; Stanczyk FZ; Reichardt JK; vanBokhoven A; Neuhouser ML; Santella RM; Figg WD; Price DK; Parnes HL; Lippman SM; Ambrosone CB; Thompson IM
    Urology; 2015 Mar; 85(3):616-20. PubMed ID: 25733274
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemoprevention for prostate cancer - the way forward?
    Fitzpatrick JM
    BJU Int; 2003 May; 91(7):589-90. PubMed ID: 12699461
    [No Abstract]   [Full Text] [Related]  

  • 55. High-grade prostate cancer and finasteride.
    Lebdai S; Bigot P; Azzouzi AR
    BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-Term Effects of Finasteride on Prostate Cancer Mortality.
    Goodman PJ; Tangen CM; Darke AK; Lucia MS; Ford LG; Minasian LM; Parnes HL; LeBlanc ML; Thompson IM
    N Engl J Med; 2019 Jan; 380(4):393-394. PubMed ID: 30673548
    [No Abstract]   [Full Text] [Related]  

  • 57. Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?
    Vickers AJ; Savage CJ; Lilja H
    J Clin Oncol; 2010 Mar; 28(7):1112-6. PubMed ID: 20124185
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Benign prostatic hyperplasia: caveat for finasteride should be discussed before prescribing.
    Ammar H; Malani AK; Gupta C
    BMJ; 2006 Sep; 333(7569):654; author reply 654. PubMed ID: 16990336
    [No Abstract]   [Full Text] [Related]  

  • 59. Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.
    Winchester DA; Till C; Goodman PJ; Tangen CM; Santella RM; Johnson-Pais TL; Leach RJ; Xu J; Zheng SL; Thompson IM; Lucia MS; Lippman SM; Parnes HL; Isaacs WB; De Marzo AM; Drake CG; Platz EA
    Prostate; 2017 Jun; 77(8):908-919. PubMed ID: 28317149
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Stat bite: Estimated effect of finasteride on prostate cancer development.
    J Natl Cancer Inst; 2003 Jul; 95(14):1031. PubMed ID: 12865443
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.